Scarica l'app Stockscreener
67.47
5.11%
3.28
Dopo l'orario di chiusura:
67.56
0.09
+0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GH Giù?
Forum
Previsione
Precedente Chiudi:
$64.19
Aprire:
$64.61
Volume 24 ore:
2.97M
Relative Volume:
1.18
Capitalizzazione di mercato:
$8.41B
Reddito:
$692.26M
Utile/perdita netta:
$-512.41M
Rapporto P/E:
-15.91
EPS:
-4.24
Flusso di cassa netto:
$-274.36M
1 W Prestazione:
+3.39%
1M Prestazione:
+21.79%
6M Prestazione:
+49.34%
1 anno Prestazione:
+212.07%
Intervallo 1D:
$64.58
$68.23
Intervallo di 1 settimana:
$61.00
$68.23
Portata 52W:
$20.14
$68.23
Guardant Health Inc Stock (GH) Company Profile
Nome
Guardant Health Inc
Settore
Industria
Telefono
855-698-8887
Indirizzo
3100 HANOVER STREET, PALO ALTO
Confronta GH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
67.47 | 7.80B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
536.78 | 198.56B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
210.92 | 147.61B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
637.34 | 50.96B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
141.10 | 39.13B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
205.75 | 34.81B | 15.70B | 1.24B | 2.01B | 6.9036 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-25 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Ripresa | Wells Fargo | Overweight |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-28 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-11-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Iniziato | Craig Hallum | Buy |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-04-28 | Ripresa | BTIG Research | Buy |
| 2022-02-24 | Reiterato | Canaccord Genuity | Buy |
| 2022-02-24 | Reiterato | Citigroup | Buy |
| 2022-02-24 | Reiterato | Cowen | Outperform |
| 2022-02-24 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-24 | Reiterato | SVB Leerink | Outperform |
| 2022-02-24 | Reiterato | Stifel | Buy |
| 2022-02-24 | Reiterato | Wells Fargo | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-11 | Iniziato | Stifel | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-06-12 | Iniziato | BTIG Research | Buy |
| 2020-02-21 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-08-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-04-16 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Reiterato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | JP Morgan | Overweight |
| 2018-10-29 | Iniziato | William Blair | Outperform |
Mostra tutto
Guardant Health Inc Borsa (GH) Ultime notizie
Is Guardant Health Inc. building a consolidation baseQuarterly Profit Summary & Real-Time Buy Zone Alerts - newser.com
Guardant Health stock hits 52-week high at 68.01 USD - Investing.com
Guardant Health And Collaborators To Present New Data Across The Cancer Care Continuum At Esmo 2025 - TradingView
Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025 - Silicon Canals
Why Guardant Health Inc. stock is recommended by analystsStock Surge & Low Drawdown Momentum Ideas - newser.com
What institutional flow reveals about Guardant Health Inc.July 2025 WrapUp & Daily Volume Surge Signals - newser.com
How to use Fibonacci retracement on Guardant Health Inc.July 2025 Opening Moves & Safe Entry Point Alerts - newser.com
Guardant Health files lawsuit against Natera for stealing trade secrets - MSN
How to track smart money flows in Guardant Health Inc.Stock Surge & Free Technical Confirmation Trade Alerts - newser.com
Can Guardant Health Inc. stock deliver consistent earnings growthTrade Entry Summary & High Accuracy Trade Alerts - newser.com
Guardant Health: Hold Rating Ahead Of Q3 Results On Valuation And Execution Risk (GH) - Seeking Alpha
Guardant Health, Inc. (GH) Stock Analysis: A Growth Powerhouse with a 6.81% Upside Potential - DirectorsTalk Interviews
What analysts say about Guardant Health Inc stockRisk-Reward Ratio Analysis & Best Stocks For Explosive Growth - earlytimes.in
Guardant Health, Inc. (NASDAQ:GH) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Using Ichimoku Cloud for Guardant Health Inc. technicals2025 Retail Activity & High Return Stock Watch Alerts - newser.com
Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025 - FinancialContent
CustomerThink - CustomerThink
Quantitative breakdown of Guardant Health Inc. recent movePortfolio Update Report & Free Expert Verified Stock Movement Alerts - newser.com
Why Guardant Health Inc. (5GH) stock stays on top picksOptions Play & AI Powered Market Entry Strategies - newser.com
Pattern recognition hints at Guardant Health Inc. upsideTake Profit & Weekly High Conviction Trade Ideas - newser.com
Abel Hall LLC Invests $202,000 in Guardant Health, Inc. $GH - MarketBeat
Published on: 2025-10-09 03:21:22 - newser.com
Guardant Health's (GH) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
What drives Guardant Health Inc 5GH stock priceAnalyst Downgrades & Market Volatility Strategies - earlytimes.in
Evercore ISI Group Raises Price Target for Guardant Health (GH) to $68 | GH Stock News - GuruFocus
Evercore ISI Raises Guardant Health (NASDAQ:GH) Price Target to $68.00 - MarketBeat
Liquid Biopsy for Early Cancer Detection and Monitoring - GlobeNewswire
Liquid Biopsy for Early Cancer Detection and Monitoring Market Report 2025-2033, with Profiles of GRAIL, AnchorDx, Burning Rock Biotech, Genecast, Guardant Health, Elypta, Freenome, and Oncimmune - Yahoo Finance
Is Guardant Health Inc. (5GH) stock dividend growth reliableTrade Performance Summary & AI Forecast for Swing Trade Picks - newser.com
Visualizing Guardant Health Inc. stock with heatmapsCPI Data & Weekly Return Optimization Plans - newser.com
What momentum shifts mean for Guardant Health Inc.Quarterly Market Review & Precise Trade Entry Recommendations - newser.com
Using economic indicators to assess Guardant Health Inc. potentialJuly 2025 Drop Watch & Smart Allocation Stock Reports - newser.com
Guardant Health Inc Stock Analysis and ForecastMarket Liquidity Analysis & Rapid Capital Trading Plans - earlytimes.in
Shareholders in Guardant Health (NASDAQ:GH) Are in the Red If They Invested Three Years Ago - 富途牛牛
Guardant Health gets FDA nod for Guardant360 CDx as a companion diagnostic - MSN
How FDA Approval of Guardant360 CDx as Companion Diagnostic Could Impact Guardant Health (GH) Investors - Yahoo Finance
Is Quest Diagnostics' (DGX) Shield Partnership Transforming Its Role in Preventive Health Innovation? - Yahoo Finance
How to use a screener to detect Guardant Health Inc. breakoutsTrade Risk Report & Smart Money Movement Alerts - newser.com
Comparing Guardant Health Inc. in custom built stock radarsJuly 2025 WrapUp & Entry Point Strategy Guides - newser.com
Risk adjusted return profile for Guardant Health Inc. analyzedMarket Sentiment Report & Daily Momentum Trading Reports - newser.com
Barclays Raises Price Target for Guardant Health (GH) to $70.00 | GH Stock News - GuruFocus
4,782 Shares in Guardant Health, Inc. $GH Purchased by Trivium Point Advisory LLC - MarketBeat
GCC Liquid Biopsy Market Forecast and Company Analysis - GlobeNewswire
GCC Liquid Biopsy Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Bio-Rad, Thermo Fisher Scientific, Johnson & Johnson, Guardant Health, QIAGEN, Sysmex - Yahoo Finance
Sicart Associates LLC Increases Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (GH) Unveils Shield V2, Boosts Early Cancer Detection Accuracy - Insider Monkey
What drives Guardant Health Inc stock priceEx-Dividend Date Alerts & Free Take Advantage Of Momentum - earlytimes.in
Stocks making big moves yesterday: Beyond Meat, The Trade Desk, Guardant Health, PayPal, and Tilray - The Globe and Mail
Guardant Health backs lung cancer screening advocacy campaign - Mugglehead Magazine
Guardant Health Inc Azioni (GH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Guardant Health Inc Azioni (GH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Monroe Terilyn J. | Chief People Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
10,477 |
0 |
31,397 |
| Kalia Kumud | Chief Information Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
10,549 |
0 |
29,713 |
| Freeman Chris | Chief Commercial Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
13,550 |
0 |
63,179 |
| EAGLE CRAIG | Chief Medical Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
13,859 |
0 |
51,341 |
| Chudova Darya | Chief Technology Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
16,104 |
0 |
97,553 |
| Bell Michael Brian | Chief Financial Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
15,181 |
0 |
59,822 |
| Talasaz AmirAli | Co-Chief Executive Officer |
Sep 30 '25 |
Option Exercise |
0.00 |
4,814 |
0 |
1,988,479 |
| Talasaz AmirAli | Co-Chief Executive Officer |
Oct 01 '25 |
Option Exercise |
0.00 |
23,997 |
0 |
2,010,036 |
| Krognes Steve E. | Director |
Sep 30 '25 |
Option Exercise |
0.00 |
154 |
0 |
18,282 |
| Eltoukhy Helmy | Co-Chief Executive Officer |
Sep 30 '25 |
Option Exercise |
0.00 |
4,814 |
0 |
2,128,313 |
0.74%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):